English | 简体中文 | 繁體中文 | 한국어 | 日本語
2023年5月4日 19時00分

來源 Envision Pharma Group
Envision Pharma Group Appoints Healthcare Industry Expert and Experienced Leader Dr. Jennifer Costello, PharmD, BCPS, CMPP, as Chief Medical Officer

PHILADELPHIA, PA, 2023年5月4日 - (亞太商訊) - Envision Pharma Group (Envision) has appointed Dr. Jennifer Costello, PharmD, BCPS, CMPP, to the role of Chief Medical Officer. Jennifer will be responsible for progressing work across all sectors of Envision's business, including Technology, Medical, Commercial, Public Affairs, and Value & Access and Data Analytics.

Meg Heim, CEO of Envision Pharma Group, adds, "I am so excited to welcome Jennifer to the Envision team as Chief Medical Officer. Jennifer's deep expertise in science and commercialization in the life sciences industry, in addition to her extensive pharmaceutical understanding and experience will further support the acceleration of our business expansion, mission, and commitment to our vision as a technology-enabled partner to the life sciences industry."

Jennifer is an accomplished pharmaceutical and healthcare leader with over 20 years of experience across the healthcare sector. She brings to this role extensive cardiovascular, medical, and patient care-related focused expertise, with a successful track record of leading high-performing cross-matrix teams with global impact.

Prior to joining Envision, Jennifer held multiple leadership roles in global medical affairs and publications, US HEOR publications, and global scientific content. She developed a reputation for leading successful partnerships with cross-functional colleagues, advocacy partners, and academic groups that resulted in building innovative programs that foster healthcare transformation.

Jennifer joins Envision from Bristol Myers Squibb, where she most recently led cardiovascular (CV) patient advocacy across its CV portfolio (early phase assets to marketed products). She drove the development and execution of global and US strategies for a successful launch of a first-in-class CV asset, working across early asset development, commercial, and medical affairs teams. For her work in this space, she was awarded the coveted "Innovation Award" from BMS.

Before joining the pharmaceutical industry, her 16 years of experience as a practicing clinical pharmacist was within the academic medical-teaching hospital. Jennifer served in numerous roles as a pediatric critical care specialist, adult ambulatory clinical care specialist, hospital administrator, and as a Director of Clinical Pharmacy Services. Under a collaborative practice agreement, she also led outpatient care optimization, directly co-managing heart failure, antithrombotic, and diabetic patients.

Jennifer received her PharmD from Northeastern University, completed her ASHP PGY-1 residency at the University of Arizona/University Medical Center, and received her board certification as a pharmacotherapy specialist from the American College of Clinical Pharmacy. She served in adjunct teaching positions with Rutgers University and the University of Florida. She has authored over 50 publications and posters and served as a pharmacy national thought leader within the heart failure, antithrombotic, and diabetes management space.

Jennifer adds, "I am delighted and humbled to join the Envision team during this transformative time. I am looking forward to meeting and working with our Envision family, customers, and partners. This is an exciting period for our industry at large, and I am privileged to build upon our company vision, award-winning technology, and innovation as medical affairs and global healthcare communication leaders."

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information
Colleen Carter
Associate Director, Communications, Office of the CEO
1 (508) 505 8856

SOURCE: Envision Pharma Group

話題 Press release summary
來源 Envision Pharma Group

部門 BioTech, Healthcare & Pharm, HR
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Envision Pharma Group Related News
Jan 18, 2024 20:00 HKT/SGT
Envision Pharma Group Welcomes Industry Veteran and HR Expert Carolyn Bartholdson as Chief People Officer
Jan 16, 2024 20:00 HKT/SGT
Envision Pharma Group Appoints Life Sciences Industry Veteran Alice Choi as President, Integrated Medical Capabilities and Solutions (IMC)
Nov 15, 2023 20:00 HKT/SGT
Envision Pharma Group Announces New AI Innovation Board and Appoints Chairwoman
June 15, 2023 19:00 HKT/SGT
OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position
May 10, 2023 14:00 HKT/SGT
Envision Pharma Group Announces Appointment of Dr. Deepti Sodhi Jaggi to Board of Directors
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575